Loading
A phase 2 trial of Scalp cooling in Breast cancer, run by Dana-Farber Cancer Institute, now recruiting.
Scalp Cooling in MBC is a phase 2 interventional study registered as NCT04986579 by Dana-Farber Cancer Institute, with 120 participants planned, started 2021-10-07 and due to reach its primary completion in 2028-06-01. Interventions recorded: Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan. Conditions recorded: Metastatic Breast Cancer, Chemotherapy-induced Alopecia.
Linked to the technology Scalp cooling because the registry names it ("scalp cooling") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Scalp cooling (cold caps: DigniCap, Paxman), Breast cancer (all types) and the tag pipeline.
Shares Scalp cooling (cold caps: DigniCap, Paxman), Breast cancer (all types) and the tag pipeline.
Shares Eribulin, Sacituzumab govitecan and the tag pipeline.
Shares Eribulin and the tag pipeline.
Shares Eribulin, Breast cancer (all types) and the tag pipeline.
Shares Eribulin and the tag pipeline.
Shares Eribulin and the tag pipeline.
Shares Eribulin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/